B cell-intrinsic TLR7 and TLR9 signatures define clinical phenotype and therapeutic response in lupus nephritis

OBJECTIVES: This study explores the expression of intracytoplasmic TLRs across diverse B cell subtypes in lupus, their association with renal activity, and their prognostic value. METHODS: We compared TLR7, TLR9, and MyD88 expression across peripheral B cell subtypes by flow cytometry, along with 29 cytokines serum levels from 28 LN patients and 26 lupus patients with extrarenal activity (NLN). After induction therapy, TLRs/MyD88 expression was reanalysed according to treatment response in LN. RESULTS: LN patients were characterised by higher frequency of MyD88+ B cells (86.5% vs 52.65%, p 0.04), predominantly in transitional cells (97.7% vs 58.7%, p 0.03). Treatment-adjusted analysis revealed the association of TLR7⁺ naïve B cells (OR 1.02, p 0.01) and TLR9 mean fluorescence intensity (MFI) in transitional B cells (OR 1.008, p 0.004) with LN. The latter, together with eotaxin (OR 1.01, p 0.01), constitute the proposed LN association model (OR 1.006 and 1.01 p 0.01, respectively). At 6-month follow-up, the responder group showed persistently elevated expression of TLR7 and TLR9 in naïve and atypical B-cell subsets, including double-negative (DN) and age-associated B cells (ABCs). The association model for renal response included TLR7 MFI in naïve B cells (OR 1 p 0.05) and TLR9 MFI in ABCs (OR 1.001 p 0.03). CONCLUSION: In LN, increased MyD88 and TLR7/TLR9 expression in early B-cell stages may promote autoreactive cell survival and differentiation into autoantibody-secreting cells, contributing to immune complex deposition and eotaxin-sustained renal inflammation. In contrast, higher TLR9 in TLR7-dependent subsets may exert a regulatory effect that, alongside induction therapy, favours nephritis resolution.

Authors

Institutions

Publication Details

Journal
Rheumatology
Published
2026-11-18
DOI
https://doi.org/10.1093/rheumatology/keag649
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

B cell-intrinsic TLR7 and TLR9 signatures define clinical phenotype and therapeutic response in lupus nephritis

Beatriz Alcalá‐Carmona, Guillermo Juárez‐Vega, Nancy R. Mejía‐Domínguez, José Luis Maravillas‐Montero et al.
1 links
Rheumatology
Systemic Lupus Erythematosus Research
article

B cell-intrinsic TLR7 and TLR9 signatures define clinical phenotype and therapeutic response in lupus nephritis

Beatriz Alcalá‐Carmona, Guillermo Juárez‐Vega, Nancy R. Mejía‐Domínguez, José Luis Maravillas‐Montero, Diana Gómez‐Martín, Samuel Govea‐Pelaéz, Jennifer Tiaré Balderas-Miranda, David Eduardo Meza-Sánchez, Fabiola Cassiano-Quezada, Jiram José Torres-Ruiz, Mauricio Arvizu-Hernández, Michelle Patricia Loeza-Uribe, María José Ostos-Prado, Yatzil Reyna-Juárez, Karina Santana-de Anda, Norma Uribe, Álvaro Sierra-Salazar
article en

Abstract

OBJECTIVES: This study explores the expression of intracytoplasmic TLRs across diverse B cell subtypes in lupus, their association with renal activity, and their prognostic value. METHODS: We compared TLR7, TLR9, and MyD88 expression across peripheral B cell subtypes by flow cytometry, along with 29 cytokines serum levels from 28 LN patients and 26 lupus patients with extrarenal activity (NLN). After induction therapy, TLRs/MyD88 expression was reanalysed according to treatment response in LN. RESULTS: LN patients were characterised by higher frequency of MyD88+ B cells (86.5% vs 52.65%, p 0.04), predominantly in transitional cells (97.7% vs 58.7%, p 0.03). Treatment-adjusted analysis revealed the association of TLR7⁺ naïve B cells (OR 1.02, p 0.01) and TLR9 mean fluorescence intensity (MFI) in transitional B cells (OR 1.008, p 0.004) with LN. The latter, together with eotaxin (OR 1.01, p 0.01), constitute the proposed LN association model (OR 1.006 and 1.01 p 0.01, respectively). At 6-month follow-up, the responder group showed persistently elevated expression of TLR7 and TLR9 in naïve and atypical B-cell subsets, including double-negative (DN) and age-associated B cells (ABCs). The association model for renal response included TLR7 MFI in naïve B cells (OR 1 p 0.05) and TLR9 MFI in ABCs (OR 1.001 p 0.03). CONCLUSION: In LN, increased MyD88 and TLR7/TLR9 expression in early B-cell stages may promote autoreactive cell survival and differentiation into autoantibody-secreting cells, contributing to immune complex deposition and eotaxin-sustained renal inflammation. In contrast, higher TLR9 in TLR7-dependent subsets may exert a regulatory effect that, alongside induction therapy, favours nephritis resolution.

Rheumatology
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Universidad Nacional Autónoma de México (MX), Tecnológico de Monterrey (MX)
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon